PURPOSETo evaluate the impact on the radiation protection policies of the radiocontaminants in Samarium-153 ethylenediamine tetramethylene phosphonate ((153)Sm-EDTMP).METHODSThe internal contamination of patients treated with (153)Sm-EDMTP for palliation of painful disseminated multiple bone metastases due to long-lived impurities was assessed by direct measurements. These measurements were coupled with dose-rate measurements close to their bodies and spectroscopic analysis of the residual activity in post-treatment radiopharmaceutical vials.RESULTSWhole-body counting carried out in six patients showed a 30-81-kBq europium -152 plus europium-154 contamination. The 0.85 mean (152)Eu- to -(154)Eu activity ratio obtained by direct counting was similar to that assessed by analysis of post-treatment residual activities in twelve radiopharmaceutical vials following radiopharmaceutical injection.CONCLUSIONSThe long-lived radiocontaminants in the patient's bodies and the treatment wastes require modifications of the applicable radiation protection policies.

01 Jan 1992·Yao xue xue bao = Acta pharmaceutica Sinica

[Studies on biotransformation of etheofazine in isolated perfused rat liver].

Article

Author: Ruan, J X ; Xu, W M ; Min, Q W ; Zhang, Z Q

The biotransformation of etheofazine (EDMTP), a new anticancer drug, was studied by using isolated perfused rat liver. Two main metabolites were separated from the perfusate by HPLC and TLC and their chemical structures were determined by MS, 1H-NMR and IR. EDMTP-I is the parent compound. EDMTP-II is 7-ethyl-8-aminotheophylline. EDMTP-II was also separated and identified from the blood of mice after iv of 10 mg/kg. Species difference of biotransformation of EDMTP between rat and mouse seems to be not significant in this study.

Yaoxue Xuebao

Biotransformation of etheofazine in isolated perfused rat liver

Author: Zhang, Z. Q. ; Ruan, J. X. ; Min, Q. W. ; Xu, W. M.

The biotransformation of etheofazine (I; R = N:NN(Me)₂), a new anticancer drug, was studied in isolated perfused rat liver.Two compounds were separated from the perfusate by HPLC and TLC and their chem. structures were determined by MS, ¹H-NMR and IR as unchanged etheofazine and its metabolite I (R = NH₂) (II).II was also separated and identified from the blood of mice after i.v. I (10 mg/kg).Species differences in the biotransformation of etheofazine between rat and mouse seems not to be significant in this study.

100 Deals associated with Etheofazine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cancer Pain	Preclinical	Greece	University of Ioannina	13 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Etheofazine

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation